Melanoma & Skin Cancer | Specialty

Dr. Luke the Role of Molecular Testing in Melanoma

November 24th 2020

Jason J. Luke, MD, FACP, discusses the role of molecular testing in melanoma.

TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market

November 24th 2020

November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.

Dr. Kudchadkar on the Durability of Immunotherapy in Non-Melanoma Skin Cancers

November 23rd 2020

Ragini Kudchadkar, MD, discusses the durability of immunotherapy in non-melanoma skin cancers.

Tebentafusp Improves OS in Frontline Metastatic Uveal Melanoma

November 23rd 2020

November 23, 2020 - Tebentafusp showed superiority in overall survival compared with investigator’s choice of therapy in patients with previously untreated metastatic uveal melanoma.

ctDNA Predicts Outcome for Frontline Immunotherapy in Metastatic Melanoma, But Not Second Line

November 20th 2020

November 20, 2020 - Circulating tumor DNAhas been found to be a reliable indicator of outcomes to treatment with frontline immune checkpoint inhibitors in patients with metastatic melanoma, but not in the second-line setting.

Experts Examine Potential Biomarkers for Immunotherapy in Melanoma

November 20th 2020

The emergence of immunotherapy in the melanoma treatment landscape has shifted the management of the disease; however, no strategies are in place to appropriately stratify patients for these potentially life-saving agents.

Artificial Intelligence Possesses Potential to Predict Response to Immunotherapy in Advanced Melanoma

November 19th 2020

November 19, 2020 - A computational method comprised of clinicodemographic variables with deep learning of pretreatment histology images may be able to effectively predict response to immunotherapy in patients with advanced melanoma.

PVSRIPO Shows Promising Antitumor Activity in Refractory Melanoma

November 14th 2020

November 14, 2020 – Treatment with the novel intratumoral immuotherapy agent PVSRIPO resulted in an overall response rate of 33% among all patients with anti–PD-1 refractory melanoma.

Investigational PI3K-γ Inhibitor Eganelisib Plus Nivolumab Elicits Early Efficacy in Head and Neck Cancer, Melanoma

November 13th 2020

November 13, 2020 - Treatment with the combination of eganelisib, a selective PI3K-γ inhibitor, and nivolumab demonstrated encouraging clinical activity and a favorable safety profile in patients with head and neck squamous cell carcinoma.

Early Efficacy Data With RP2 in Advanced Solid Tumors

November 13th 2020

Francesca Aroldi, discusses the early efficacy data with RP2 in advanced solid tumors.

x